Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Haematologica|August 5, 2017
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approachIris de Weerdt, Suzanne M Koopmans, Arnon P Kater, et al.
Ejhaem|July 18, 2022
Real-world experience: Introduction of T cell replete haploidentical transplantations in a single centerGwendolyn van Gorkom, Evy Billen, Catharina Van Elssen, et al.
Medicine, Health Care, and Philosophy|October 21, 2016
Permitting patients to pay for participation in clinical trials: the advent of the P4 trialDavid Shaw, Guido de Wert, Wybo Dondorp, et al.
Acta Dermato-Venereologica|March 28, 2009
T-cell large granular lymphocytic leukaemia with an uncommon clinical and immunological phenotypeMaurice A M van Steensel, Michel van Gelder, Ariënne M W van Marion, et al.
Breast Cancer Research and Treatment|December 5, 2016
Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancerMichel van Gelder, Ariane Vanclée, Catharina H M J van Elssen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2011
Compartmentalization of acyclovir-resistant varicella zoster virus: implications for sampling in molecular diagnosticsAntoinette A T P Brink, Michel van Gelder, Petra F Wolffs, et al.
Blood|July 13, 2018
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapiesPeter Dreger, Paolo Ghia, Johannes Schetelig, et al.
Blood|October 11, 2014
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Peter Dreger, Johannes Schetelig, Niels Andersen, et al.
Plos One|June 1, 2013
Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cellsSubhashis Sarkar, Wilfred T V Germeraad, Kasper M A Rouschop, et al.
Cancers|July 2, 2021
ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer ResponseFemke A I Ehlers, Nicky A Beelen, Michel van Gelder, et al.
Pageof 6